{"id":390088,"date":"2021-03-04T00:00:00","date_gmt":"2021-03-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2021\/"},"modified":"2026-05-15T23:17:34","modified_gmt":"2026-05-15T23:17:34","slug":"algoim0057-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2021\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2021"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea predominant subtype. Limited treatment options are available for IBS, and only a few drugs have secured FDA approval for IBS-D. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals\u2019 Lotronex), an antibiotic (Salix Pharmaceuticals\u2019 Xifaxan), and an opioid delta receptor antagonist (AbbVie\u2019s Viberzi).<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?<\/li>\n<li>How have Viberzi and Xifaxan been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p><strong>Markets covered:<\/strong> United States.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Salix, Sebela\u00a0Pharmaceuticals.<\/p>\n<p><strong>Key drugs:<\/strong> Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate \/ scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate.<\/p>\n","protected":false},"template":"","class_list":["post-390088","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390088\/revisions"}],"predecessor-version":[{"id":393213,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390088\/revisions\/393213"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}